top of page
frustrated.jpg

Current treatments are ineffective or only provide transient relief from symptoms and/or cause harm to the microbiome

It's all in the numbers

stats.png
image (2).png

Observations from a clinical study suggest that the SMMRT asset, PTx838, is capable of:

  • Halts the growth of pro-inflammatory yeast and E. coli, AND

  • Induces the growth of healthy Lactobacillus spp.

Clinical Impact

Baseline (BV)

High E. coli

image (1).png

PTx838-Treated (t=48 hr)

Low/No E.coli,

Significant Lactobacillus growth

bottom of page